Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Ovarian Cancer: Optimizing Treatment With Niraparib

November 20th 2017

Treating Ovarian Cancer With Niraparib: The NOVA Trial

November 20th 2017

Platinum-Sensitive Relapsed Ovarian Cancer: Rucaparib

November 20th 2017

Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer

November 20th 2017

PARP Inhibitors' Impact on Advanced Ovarian Cancer

November 20th 2017

Ovarian Cancer: Considerations for Molecular Testing

November 20th 2017

Ovarian Cancer: Testing for Mutations

November 20th 2017

Molecular Testing in Ovarian Cancer

November 20th 2017

Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC

November 18th 2017

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Dr. McCollum on Treatment in the First-Line Setting for CRC

November 17th 2017

A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

Ramalingam Expands on Osimertinib Updates in NCCN Guidelines for EGFR+ NSCLC

November 14th 2017

Suresh A. Ramalingam, MD, discusses some of the changes to the NCCN guidelines in non-small cell lung cancer, specifically with EGFR-mutation–positive disease, and how the frontline recommendation of osimertinib will impact clinical practice.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017